|
|
|
|
The value of Tzanck smear test in diagnosis of erosive, vesicular, bullous, and pustular skin lesions
Durdu M et al.- Tzanck smear was performed in a total of 400 patients with moist skin lesions. The sensitivities of multinucleated giant cells and acantholytic cells in herpetic infections, dyskeratotic acantholytic cells and cocci in...
|
|
|
Spotlight on Retapamulin in Impetigo and Other Uncomplicated Superficial Skin Infections
Yang LPH et al.- The introduction of topical retapamulin 1% ointment extends the treatment options available in the management of impetigo and uncomplicated secondarily infected traumatic lesions. Spotlight on Retapamulin in ...
|
|
|
Perrigo Company Licenses Prescription Brands to Medimetriks Pharmaceuticals
- (NewsRx.com) -- Medimetriks Pharmaceuticals announced that the Company entered into a licensing agreement with Perrigo Company (NASDAQ:PRGO) for the U.S.marketing rights to Centany(R) Ointment and two prescription keratolytic brands.
|
|
|
Perrigo Licenses Prescription Brands to Medimetriks Pharmaceuticals
Medimetriks Pharmaceuticals has announced that the company has entered into a licensing agreement with Perrigo Company for the U.S.marketing rights to Centany(R) Ointment and two prescription keratolytic brands. Patented through 2018,...
|
|
|
Perrigo Company Licenses Prescription Brands to Medimetriks Pharmaceuticals
Medimetriks Adds Centany(R) (mupirocin ointment, 2%) and Two New Brands to Dermatology and Podiatry Product Portfolio FAIRFIELD, N.J., Oct.28 /PRNewswire/ -- Medimetriks Pharmaceuticals announced today that the Company entered into a...
|
|
|
Perrigo Company Licenses Prescription Brands to Medimetriks Pharmaceuticals
Medimetriks Adds Centany(R) (mupirocin ointment, 2%) and Two New Brands to Dermatology and Podiatry Product Portfolio FAIRFIELD, N.J., Oct.28 /PRNewswire/ -- Medimetriks Pharmaceuticals announced today that the Company entered into a...
|
|
|
Medimetriks announces agreement to market treatments for impetigo
_ Medimetriks announces agreement to market treatments for impetigo.
|
|
|
Perrigo Company Licenses Prescription Brands to Medimetriks Pharmaceuticals
Medimetriks Adds Centany (mupirocin ointment, 2%) and Two New Brands to Dermatology and Podiatry Product PortfolioFAIRFIELD, N.J., Oct.28 (HSMN NewsFeed) -- Medimetriks Pharmaceuticals announced today that the Company entered into a...
|
|
|
Perrigo Company Licenses Prescription Brands to Medimetriks Pharmaceuticals
Medimetriks Adds Centany(R) (mupirocin ointment, 2%) and Two New Brands to Dermatology and Podiatry Product Portfolio FAIRFIELD, N.J., Oct.28 /PRNewswire/ -- Medimetriks Pharmaceuticals announced today that the Company entered into a...
|
|
|
Perrigo Company Licenses Prescription Brands to Medimetriks Pharmaceuticals
Medimetriks Adds Centany(R) (mupirocin ointment, 2%) and Two New Brands to Dermatology and Podiatry Product Portfolio FAIRFIELD, N.J., Oct.28 /PRNewswire/ -- Medimetriks Pharmaceuticals announced today that the Company entered into a...
|
|
|
Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/I
- Once-a-Day Radezolid Clinically and Microbiologically As Effective As Twice-a-Day Linezolid When Used to Treat a Variety of uSSSIs - NEW HAVEN, Conn., Oct.26 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc. ('Rib-X' or the 'Company'), a...
|
|
|
Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/I
- Once-a-Day Radezolid Clinically and Microbiologically As Effective As Twice-a-Day Linezolid When Used to Treat a Variety of uSSSIs - NEW HAVEN, Conn., Oct.26 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc. ('Rib-X' or the 'Company'), a...
|
|
|
Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/I
- Once-a-Day Radezolid Clinically and Microbiologically As Effective As Twice-a-Day Linezolid When Used to Treat a Variety of uSSSIs - NEW HAVEN, Conn., Oct.26 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc. ('Rib-X' or the 'Company'), a...
|
|
|
Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/I
- Once-a-Day Radezolid Clinically and Microbiologically As Effective As Twice-a-Day Linezolid When Used to Treat a Variety of uSSSIs - NEW HAVEN, Conn., Oct.26 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc. ('Rib-X' or the 'Company'), a...
|
|
|
Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 20
- Once-a-Day Radezolid Clinically and Microbiologically As Effective As Twice-a-Day Linezolid When Used to Treat a Variety of uSSSIs - NEW HAVEN, Conn., Oct.26 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc. ('Rib-X' or the 'Company'), a...
|
|
|
Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/I
- Once-a-Day Radezolid Clinically and Microbiologically As Effective As Twice-a-Day Linezolid When Used to Treat a Variety of uSSSIs - NEW HAVEN, Conn., Oct.26 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc. ('Rib-X' or the 'Company'), a...
|
|
|
Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/I
- Once-a-Day Radezolid Clinically and Microbiologically As Effective As Twice-a-Day Linezolid When Used to Treat a Variety of uSSSIs - NEW HAVEN, Conn., Oct.26 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc. ('Rib-X' or the 'Company'), a...
|
|
|
Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/I
- Once-a-Day Radezolid Clinically and Microbiologically As Effective As Twice-a-Day Linezolid When Used to Treat a Variety of uSSSIs - NEW HAVEN, Conn., Oct.26 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc. ('Rib-X' or the 'Company'), a...
|
|
|
Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/I
- Once-a-Day Radezolid Clinically and Microbiologically As Effective As Twice-a-Day Linezolid When Used to Treat a Variety of uSSSIs - NEW HAVEN, Conn., Oct.26 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc. ('Rib-X' or the 'Company'), a...
|
|
|
Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/I
- Once-a-Day Radezolid Clinically and Microbiologically As Effective As Twice-a-Day Linezolid When Used to Treat a Variety of uSSSIs - NEW HAVEN, Conn., Oct.26 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc. ('Rib-X' or the 'Company'), a...
|
|
|
Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/I
- Once-a-Day Radezolid Clinically and Microbiologically As Effective As Twice-a-Day Linezolid When Used to Treat a Variety of uSSSIs - NEW HAVEN, Conn., Oct.26 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc. ('Rib-X' or the 'Company'), a...
|
|
|
Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/I
- Once-a-Day Radezolid Clinically and Microbiologically As Effective As Twice-a-Day Linezolid When Used to Treat a Variety of uSSSIs - NEW HAVEN, Conn., Oct.26 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc. ('Rib-X' or the 'Company'), a...
|
|
|
Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/I
- Once-a-Day Radezolid Clinically and Microbiologically As Effective As Twice-a-Day Linezolid When Used to Treat a Variety of uSSSIs - NEW HAVEN, Conn., Oct.26 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc. ('Rib-X' or the 'Company'), a...
|
|
|
Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/I
- Once-a-Day Radezolid Clinically and Microbiologically As Effective As Twice-a-Day Linezolid When Used to Treat a Variety of uSSSIs - NEW HAVEN, Conn., Oct.26 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc. ('Rib-X' or the 'Company'), a...
|
|
|
Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/I
- Once-a-Day Radezolid Clinically and Microbiologically As Effective As Twice-a-Day Linezolid When Used to Treat a Variety of uSSSIs - NEW HAVEN, Conn., Oct.26 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc. ('Rib-X' or the 'Company'), a...
|
